{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Manifestations&page=5",
    "query": {
      "condition": "Oral Manifestations",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 479,
    "total_pages": 48,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Manifestations&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Manifestations&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T03:47:03.712Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03848832",
      "title": "Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rett Syndrome",
        "RTT"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 29,
      "start_date": "2019-07-29",
      "completion_date": "2021-01-21",
      "has_results": true,
      "last_update_posted_date": "2022-09-02",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848832"
    },
    {
      "nct_id": "NCT01251263",
      "title": "Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menstrual Migraines",
        "Menstrual Bleeding",
        "Menstrual Spotting"
      ],
      "interventions": [
        {
          "name": "Estradiol or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scott and White Hospital & Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2010-10",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2010-12-01",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251263"
    },
    {
      "nct_id": "NCT02217007",
      "title": "A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "SNC-102 sustained release tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synchroneuron Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-04",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Manhasset, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02217007"
    },
    {
      "nct_id": "NCT06226454",
      "title": "A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "VX-993",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2024-01-04",
      "completion_date": "2024-06-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06226454"
    },
    {
      "nct_id": "NCT01727700",
      "title": "Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tourette's Disorder",
        "Tic Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 133,
      "start_date": "2012-11",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-02-13",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 55,
      "location_summary": "Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 52 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01727700"
    },
    {
      "nct_id": "NCT00235053",
      "title": "Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Candidiasis, Oral",
        "Voice Disorders"
      ],
      "interventions": [
        {
          "name": "fluticasone/salmeterol DISKUS 250/50",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergy & Asthma Medical Group & Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2005-08",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235053"
    },
    {
      "nct_id": "NCT04826237",
      "title": "Oral Statins and Protection From Hearing Loss",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sudden Sensorineural Hearing Loss"
      ],
      "interventions": [
        {
          "name": "Statin",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2023-02-09",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04826237"
    },
    {
      "nct_id": "NCT00556075",
      "title": "Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Proellex 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Proellex 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "48 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 48 Years · Female only"
      },
      "enrollment_count": 67,
      "start_date": "2007-11",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2014-08-25",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556075"
    },
    {
      "nct_id": "NCT01167335",
      "title": "Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Partial Onset Seizures"
      ],
      "interventions": [
        {
          "name": "BGG492",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-05-01",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 3,
      "location_summary": "Mobile, Alabama • Baltimore, Maryland • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01167335"
    },
    {
      "nct_id": "NCT01727713",
      "title": "Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tourette's Disorder",
        "Tic Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "7 Years to 18 Years"
      },
      "enrollment_count": 110,
      "start_date": "2013-01",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-10-16",
      "last_synced_at": "2026-10-12T03:47:03.712Z",
      "location_count": 26,
      "location_summary": "Dothan, Alabama • Goodyear, Arizona • Orange, California + 23 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Wildomar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01727713"
    }
  ]
}